Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 12.25%, which has investors questioning if this is right time ...

Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 15.10%, which has investors questioning if this is right time to sell.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Recently recognised as a desmosomal disorder, autoimmune pemphigus remains severe in some of its forms, such as pemphigus vulgaris. This review is divided into four parts. “Cellular and molecular ...

This might be Pearce’s best book yet. Elise, the protagonist of Sarsfield’s ambitious, impressive debut, BETA VULGARIS (Norton, 285 pp., paperback, $18.99), isn’t poor; she’s “broke.” ...

In contrast to pemphigus vulgaris, PF does not usually involve the mucous membranes and is associated with less morbidity and lower mortality. Treatment involves topical corticosteroids and ...

Methods to get rid of pimples include using home remedies, over-the-counter (OTC) products, and prescription medications. Unfortunately, popping pimples may lead to more inflammation, longer healing ...

The most common lilac is Syringa vulgaris, or tree lilac. Native to east Asia and south-east Europe, it was much loved by the Edwardians and was widely grown in suburban gardens before going out of ...

Muhaidat J, Qablan A, Gharaibeh F, et al. The effect of whey protein supplements on acne vulgaris among male adolescents and young adults: A case-control study from north of Jordan. Dermatol Res ...

Issues to be addressed when evaluating a patient for pemphigus include the age of onset, previous clinical symtoms, initial presentation, presence of mucous membrane symptoms and the presence of ...

A host of concerns weighed on Immunovant’s stock price, the most critical of which was competitor argenx SE’s failure in pemphigus vulgaris, which has raised questions about the addressable ...